■ Nova Eye Medical has established the iTrack Global Data Registry to collect prospective, multicenter, longitudinal data for canaloplasty in the treatment of glaucoma, according to a news release. The registry is part of a collaboration with the International Glaucoma Surgery Registry, and will be led by surgeons Ike K. Ahmed, MD, FRCSC; David Lubeck, MD; and Nathan Kerr, BHB, MBChB, MD, FRANZCO, with the support of an educational grant from Nova Eye Medical. The registry, spearheaded by Dr. Kerr and featuring Nova’s canaloplasty devices iTrack and iTrack Advance, will capture real-world clinical evidence for canaloplasty across Europe, the Asia Pacific region, and North America.

“The iTrack Global Data Registry is providing high-quality, real-world evidence of the effectiveness and safety of canaloplasty to treat glaucoma and ocular hypertension. Importantly, it provides a robust means by which to collect uniform data to evaluate specified outcomes across the spectrum of glaucoma. It will make a major contribution to our understanding of the clinical effectiveness of canaloplasty and will enable evidence-based decision making,” Dr. Kerr said in a news release. GP